Literature DB >> 29066308

Synthesis and anti-HCV activity of a series of β-d-2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs.

Zhe Chen1, Bryan D Cox1, Ethel C Garnier-Amblard2, Tamara R McBrayer2, Steven J Coats2, Raymond F Schinazi3, Franck Amblard4.   

Abstract

Several β-d-2'-deoxy-2'-substituted nucleoside analogs have displayed potent and selective anti-HCV activities and some of them have reached human clinical trials. In that regard, we report herein the synthesis of a series of 2'-deoxy,2'-dibromo substituted U, C, G and A nucleosides 10a-d and their corresponding phosphoramidate prodrugs 13a-d. The synthesized nucleosides 10a-d and prodrugs 13a-d were evaluated for their inhibitory activity against HCV as well as cellular toxicity. The results showed that the most potent compound was prodrug 13a, which exhibited micromolar inhibitory activity (EC50 = 1.5 ± 0.8 µM) with no observed toxicity. In addition, molecular modeling and free energy perturbation calculations for the 5'-triphosphate formed from 13a and related 2'-modified nucleotides are discussed.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hepatitis C virus; Nucleoside; Prodrug; Synthesis

Mesh:

Substances:

Year:  2017        PMID: 29066308      PMCID: PMC5693771          DOI: 10.1016/j.bmcl.2017.10.024

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  22 in total

1.  Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture.

Authors:  Lieven J Stuyver; Tony Whitaker; Tamara R McBrayer; Brenda I Hernandez-Santiago; Stefania Lostia; Phillip M Tharnish; Mangala Ramesh; Chung K Chu; Robert Jordan; Junxing Shi; Suguna Rachakonda; Kyoichi A Watanabe; Michael J Otto; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

2.  Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field.

Authors:  Lingle Wang; Yujie Wu; Yuqing Deng; Byungchan Kim; Levi Pierce; Goran Krilov; Dmitry Lupyan; Shaughnessy Robinson; Markus K Dahlgren; Jeremy Greenwood; Donna L Romero; Craig Masse; Jennifer L Knight; Thomas Steinbrecher; Thijs Beuming; Wolfgang Damm; Ed Harder; Woody Sherman; Mark Brewer; Ron Wester; Mark Murcko; Leah Frye; Ramy Farid; Teng Lin; David L Mobley; William L Jorgensen; Bruce J Berne; Richard A Friesner; Robert Abel
Journal:  J Am Chem Soc       Date:  2015-02-12       Impact factor: 15.419

3.  Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.

Authors:  M P Curry; E B Tapper; B Bacon; D Dieterich; S L Flamm; L Guest; K V Kowdley; Y Lee; S Milligan; N Tsai; Z Younossi; N H Afdhal
Journal:  Aliment Pharmacol Ther       Date:  2017-07-10       Impact factor: 8.171

4.  Synthesis of diastereomerically pure nucleotide phosphoramidates.

Authors:  Bruce S Ross; P Ganapati Reddy; Hai-Ren Zhang; Suguna Rachakonda; Michael J Sofia
Journal:  J Org Chem       Date:  2011-09-26       Impact factor: 4.354

Review 5.  Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs.

Authors:  Jadd Shelton; Xiao Lu; Joseph A Hollenbaugh; Jong Hyun Cho; Franck Amblard; Raymond F Schinazi
Journal:  Chem Rev       Date:  2016-11-23       Impact factor: 60.622

Review 6.  Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.

Authors:  Adrian S Ray; Marshall W Fordyce; Michael J M Hitchcock
Journal:  Antiviral Res       Date:  2015-11-27       Impact factor: 5.970

7.  The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C.

Authors:  Ivan Gentile; Alberto Enrico Maraolo; Antonio Riccardo Buonomo; Emanuela Zappulo; Guglielmo Borgia
Journal:  Expert Opin Drug Discov       Date:  2015-11-12       Impact factor: 6.098

Review 8.  Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.

Authors:  Alan Hoi Lun Yau; Eric M Yoshida
Journal:  Can J Gastroenterol Hepatol       Date:  2014-09

9.  Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase.

Authors:  Todd C Appleby; Jason K Perry; Eisuke Murakami; Ona Barauskas; Joy Feng; Aesop Cho; David Fox; Diana R Wetmore; Mary E McGrath; Adrian S Ray; Michael J Sofia; S Swaminathan; Thomas E Edwards
Journal:  Science       Date:  2015-02-13       Impact factor: 47.728

Review 10.  Hepatitis C virus-induced hepatocellular carcinoma.

Authors:  Nicolas Goossens; Yujin Hoshida
Journal:  Clin Mol Hepatol       Date:  2015-06-26
View more
  6 in total

1.  Nucleoside Analogs with Antiviral Activity against Yellow Fever Virus.

Authors:  Keivan Zandi; Franck Amblard; Sarah Amichai; Leda Bassit; Sijia Tao; Yong Jiang; Longhu Zhou; Olivia Ollinger Russell; Seema Mengshetti; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

2.  Application of Molecular Dynamics Simulations to the Design of Nucleotide Inhibitors Binding to Norovirus Polymerase.

Authors:  Holly Freedman; Juthika Kundu; Egor Petrovitch Tchesnokov; John Lok Man Law; James A Nieman; Raymond F Schinazi; D Lorne Tyrrell; Matthias Gotte; Michael Houghton
Journal:  J Chem Inf Model       Date:  2020-12-01       Impact factor: 4.956

3.  In silico design of a novel nucleotide antiviral agent by free energy perturbation.

Authors:  Dharmeshkumar Patel; Bryan D Cox; Mahesh Kasthuri; Seema Mengshetti; Leda Bassit; Kiran Verma; Olivia Ollinger-Russell; Franck Amblard; Raymond F Schinazi
Journal:  Chem Biol Drug Des       Date:  2022-04-07       Impact factor: 2.873

4.  Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.

Authors:  Seema Mengshetti; Longhu Zhou; Ozkan Sari; Coralie De Schutter; Hongwang Zhang; Jong Hyun Cho; Sijia Tao; Leda C Bassit; Kiran Verma; Robert A Domaoal; Maryam Ehteshami; Yong Jiang; Reuben Ovadia; Mahesh Kasthuri; Olivia Ollinger Russell; Tamara McBrayer; Tony Whitaker; Judy Pattassery; Maria Luz Pascual; Lothar Uher; Biing Y Lin; Sam Lee; Franck Amblard; Steven J Coats; Raymond F Schinazi
Journal:  J Med Chem       Date:  2019-02-07       Impact factor: 7.446

5.  Diastereoselective Synthesis of 2'-Dihalopyrimidine Ribonucleoside Inhibitors of Hepatitis C Virus Replication.

Authors:  Longhu Zhou; Hongwang Zhang; Chengwei Li; Coralie De Schutter; Ozkan Sari; Seema Mengshetti; Shaoman Zhou; Mahesh Kasthuri; Steven J Coats; Raymond F Schinazi; Franck Amblard
Journal:  ACS Omega       Date:  2021-12-22

6.  The Inhibitory Potential of 2'-dihalo Ribonucleotides against HCV: Molecular Docking, Molecular Simulations, MM-BPSA, and DFT Studies.

Authors:  Ahmed Khalil; Amany S El-Khouly; Eslam B Elkaeed; Ibrahim H Eissa
Journal:  Molecules       Date:  2022-07-15       Impact factor: 4.927

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.